Pharma & Human Health
Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease
Synlogic, Inc. (Nasdaq: SYBX), announced that new preclinical data from SYNB1020, a Synthetic Biotic medicine currently being evaluated in an ongoing Phase 1b/2a clinical trial in patients with cirrhosis and elevated ammonia, were presented at Digestive […]